Nanobiotix Newswire

Comprehensive Real-Time News Feed for Nanobiotix.

Results 1 - 20 of 39 in Nanobiotix

  1. Carbon nanotube maker Bio-Pact moves HQ from Arizona to CambridgeRead the original story w/Photo

    Wednesday Jan 7 | Business Journal

    ... but today the company announced it will be based at 245 First St. in Cambridge. Among the others Patrick met is Nanobiotix, which announced last September it would move to Boston, and the other three are still considering coming to the state, ...

    Comment?

  2. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Wednesday Jan 7 | Business Wire

    Nanobiotix 2014 Review, 2015 Anticipated Milestones and Financial Calendar Nanobiotix Moved up to a New Level: Major Clinical and Financial Progress, Broadening of Indications and Strategic Plans To Develop across Europe, Asia and the US )--Regulatory News: NANOBIOTIX , a late clinical-stage nanomedicine company pioneering novel approaches for the local treatmen... Finnair Signed a Letter of Intent: Staffpoint and GWS to Become Shareholders in a Joint Venture Focused on Regional Flying )--Regulatory News: Finnair has signed a letter of intent with StaffPoint Holding Ltd and G.W. Sohlberg Ltd., in accordance with which Flybe UK Ltd's 60 % owners... )--Regulatory News: Skanska Skanska has signed a contract with NYU Langone Medical Center to build a new medical center in New York City.

    Comment?

  3. Report Published: "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014"Read the original story

    Sunday Dec 28 | PR-inside.com

    ... Santaris Pharma A/S, CEL-SCI Corporation, OXiGENE, Inc., Takara Bio Inc., Panacea Biotec Limited, PCI Biotech AS, Nanobiotix, Acceleron Pharma, Inc., Virttu Biologics Limited, Ascenta Therapeutics,

    Comment?

  4. New Market Research Report: Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014Read the original story

    Dec 17, 2014 | PR-inside.com

    ... Santaris Pharma A/S, CEL-SCI Corporation, OXiGENE, Inc., Takara Bio Inc., Panacea Biotec Limited, PCI Biotech AS, Nanobiotix, Acceleron Pharma, Inc., Virttu

    Comment?

  5. Nanobiotix Places Shares And Warrants With U.S. InvestorRead the original story

    Nov 30, 2014 | BioSpace

    NANOBIOTIX , a clinical-stage French nanomedicine company working on the local treatment of cancer, and listed on Euronext, Paris, announced the completion of a private placement on November 24, 2014.

    Comment?

  6. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Dec 1, 2014 | Business Wire

    Hostess Brands Invites Fans to Join the Sweetest Mission Ever and Celebrate the Penguins of Madagascar Release with Operation Hostess Holiday Sweepstakes )--Hostess Introduces Gingerbread Spice Donettes for a Limited Time in Packaging Featuring the Penguins of Madagascar; Fans Can Win a Grand Prize Trip to D.C., or a ... )--As Agent Bank, please be advised of the following rate determined on: 12/1/2014 Issue A Bluestone Securities plc - Series 2005-01 GBP 94,500,000 Class A Notes due 01 Jun 20... )--Regulatory News: Solteq In the NASDAQ OMX Helsinki Trade date 1.12.2014 Bourse trade Buy Share STQ1V Amount 1000 Shares Total cost 1 430,00 EUR Average pric... )--Viscount Systems , a leading provider of IT-based security software and services, has been recognized by Government Security News as a winn... )--Regulatory News: NANOBIOTIX , sociA tA franA aise pionniA re en ... (more)

    Comment?

  7. New Market Research Report: Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014Read the original story

    Nov 10, 2014 | PR-inside.com

    ... Santaris Pharma A/S, CEL-SCI Corporation, OXiGENE, Inc., Takara Bio Inc., Panacea Biotec Limited, PCI Biotech AS, Nanobiotix, Acceleron Pharma, Inc., Virttu Biologics Limited, Ascenta Therapeutics, Inc., Onconova Therapeutics, Inc.

    Comment?

  8. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Nov 5, 2014 | Business Wire

    ... film it? Des Moines-based financial professional, Jenny Smith, found out firs... )--Regulatory News: Nanobiotix (Paris:NANO): Place de cotation : Euronext Paris de Nyse Euronext Compartiment : Compartiment C Code ISIN : FR0011341205 Site web : ...

    Comment?

  9. Experts cautious over Google...Read the original story w/Photo

    Oct 29, 2014 | Bangkok Post

    ... stroke or heart attack. "The idea isn't new," said Laurent Levy, founder and chairman of a French company, Nanobiotix, which is looking at the use of nanoparticles in cancer radiotherapy. "It's not science fiction -- it is achievable," he told AFP, ...

    Comment?

  10. Nanobiotix Receives First Approval To Start Phase 2/3 Registration...Read the original story

    Oct 16, 2014 | BioSpace

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma . Patients with locally advanced STS have very limited therapeutic options.

    Comment?

  11. Nanobiotix Receives First Approval to St ...Read the original story

    Oct 16, 2014 | The Financial Mirror

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announced today that it has received approval from the French National Security Agency for Medicines and Health Products to start its Phase II/III registration trial of its lead product, NBTXR3, in patients with locally advanced Soft Tissue Sarcoma . Patients with locally advanced STS have very limited therapeutic options.

    Comment?

  12. European Commission opens the gate towards the implementation of Nanomedicine Translation HubRead the original story

    Oct 15, 2014 | Science, Industry and Business

    ... need of assistance in specific areas of expertise. Coordinator: ETPN Secretariat c/o VDI/VDE-IT (DE) Consortium: Nanobiotix (FR), CEA-Leti (FR), Bioanalytik Muenster e.V. (DE), Tel-Aviv University (IL), Fondazione Don Carlo Gnocchi ONLUS (IT), and ...

    Comment?

  13. Nanobiotix Reaches The Second Milestone Payment Of Dedicated To...Read the original story

    Oct 13, 2014 | BioSpace

    NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the second payment of a 1.144 k from Bpifrance as part as the funding granted to support the NICE consortium. Taking into account the development of the Strategic Industrial Innovation program and based on the completion of the first milestone "Etape clA 1", Bpifrance has proceed to transfer a 1.144 k to Nanobiotix.

    Comment?

  14. Onxeo reaches second milestone of BPIFrance grant dedicated to...Read the original story w/Photo

    Oct 10, 2014 | Business Wire

    ... in phase III and the company expects to complete the study in 2016. In addition to Onxeo, the consortium includes Nanobiotix, developer of NBTXR3, a potentiator of radiation therapy in the local treatment of cancer; CEA-Leti, developer of the ...

    Comment?

  15. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story

    Oct 8, 2014 | Business Wire

    ... Market Out... )--PharmaEngine Inc. (TWO: 4162), a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. (Euronext: NANO), a clinical-stage nanomedicine com... Research and Markets: Global Filling Equipment Market Outlook ...

    Comment?

  16. PharmaEngine, Nanobiotix Enter Global Pivotal Trial of PEP503 (NBTXR3) in Soft Tissue SarcomaRead the original story w/Photo

    Oct 8, 2014 | Business Wire

    PharmaEngine Inc. , a biopharmaceutical company developing new cancer treatments, and Nanobiotix S.A. , a clinical-stage nanomedicine company pioneering in novel approaches for local treatment of cancer, announced today that the companies had strengthened their collaboration by jointly conducting a global pivotal trial of NBTXR3 in soft tissue sarcoma in Europe and Asia. Nanobiotix expects recruitment of the first patient in Europe by the end of 2014.

    Comment?

  17. PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in...Read the original story

    Oct 7, 2014 | PR-inside.com

    Small but heading for the big time PharmaEngine will join Nanobiotix' pivotal trial for NBTXR3 in Soft Tissue Sarcoma to accelerate its development in Asia-Pacific PharmaEngine to make milestone payment to Nanobiotix in October 2014 to recognize the value created Paris, France, 8 October, 2014 - NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer today announces the update of the development plan for NBTXR3. Nanobiotix and its partner PharmaEngine Inc.,a biopharmaceutical company focusing on the development of in- licensed oncology drugs, reinforce their collaboration to obtain faster market authorization for NBTXR3 in the Asia-Pacific region.

    Comment?

  18. French Cancer Treatment Developer To Expand To U.S. With Boston OfficeRead the original story

    Sep 23, 2014 | Banker & Tradesman

    Laurent Lvy, CEO of Nanobiotix, and Gov. Deval Patrick officially announced the opening of the company's U.S. affiliate during a ceremony on Sept. 19 at the U.S. embassy in Paris in the company of Susan Windham-Bannister, CEO and President of the Massachusetts Life Sciences Center.

    Comment?

  19. French biotech Nanobiotix to open 1st U.S. office in BostonRead the original story w/Photo

    Sep 23, 2014 | Business Journal

    Nanobiotix, a France-based developer of potential therapies to treat cancer, said it intends to open its first U.S. office in Boston.

    Comment?

  20. Nanobiotix Expands Operations Into The U.S.A. As Part Of Its International Development StrategyRead the original story

    Sep 22, 2014 | BioSpace

    Affiliate opened in the Massachusetts Life Sciences Center A senior pharmaceutical executive appointed as Vice President Corporate Development Paris, France, September 22, 2014 - NANOBIOTIX , a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today the opening of its first US office in Boston, Massachusetts, the global center for life sciences.

    Comment?